Core Viewpoint - Lijun Pharmaceutical Group has received the acceptance notice from the National Medical Products Administration for the domestic production registration of JP-1366 tablets, an innovative potassium ion competitive acid blocker (P-CAB) [1] Group 1: Product Information - JP-1366 tablets work by competitively blocking the K(+) channel of the H(+), K(+)-ATPase (proton pump), inhibiting the binding of K(+) to the proton pump, thereby suppressing gastric acid secretion [1] - The product promotes esophageal mucosal healing and improves reflux symptoms, with a rapid increase in gastric pH and the ability to maintain gastric pH above 4 for an extended period, effectively addressing nighttime acid breakthrough [1] Group 2: Financial Investment - As of the announcement date, the total research and development expenses directly invested in JP-1366 tablets amount to approximately RMB 185.21 million [1]

格隆汇8月15日丨健康元(600380.SH)公布，控股子公司丽珠医药集团股份有限公司（简称：丽珠集团） 收到国家药品监督管理局核准签发的《受理通知书》，丽珠集团申请的JP-1366片的境内生产药品注册 获药监局受理。JP-1366片是一款创新钾离子竞争性酸阻滞剂（P-CAB），可以通过竞争性阻断H(+)、 K(+)-ATP酶(质子泵)的K(+)通道，阻滞K(+)与质子泵的结合，抑制胃酸的分泌，从而达到促进食管黏膜 愈合和改善反流症状的效果。JP-1366片提升胃内pH值的速率较快，且可长时间维持胃内pH值＞4，能 有效地解决夜间酸突破。 ...